Diabetic foot ulcers and amputations: Estimates of health utility for use in cost-effectiveness analyses of new treatments

Diabetes and Metabolism

Volumn 30, Issue 6, 2004, Pages 549-556

  Redekop, W K ^a   Stolk, E A ^a   Kok, E ^a   Lovas, K ^b   Kalo, Z ^b   Busschbach, J J V ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Amputations; Diabetic foot ulcers; Health utility; Health related quality of life; Quality adjusted life years

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC FOOT; FEMALE; FOOT AMPUTATION; HEALTH CARE COST; HEALTH STATUS; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RATING SCALE;

EID: 11244252336     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70154-4     Document Type: Article

References (34)

1. Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg, 1998, 176, 5S-10S.
2. Apelqvist J, Bakker K, van Houtum WH, Nabuurs-Franssen MH, Schaper NC. International consensus and practical guidelines on the management and the prevention of the diabetic foot. International Working Group on the Diabetic Foot. Diabetes Metab Res Rev, 2000, 16, S84-92.
3. Vileikyte L. Diabetic foot ulcers: a quality of life issue. Diabetes Metab Res Rev, 2001, 17, 246-9.
4. Redekop WK, McDonnell J, Verboom P, Lovas K, Kalo Z. The cost effectiveness of apligraf((r)) treatment of diabetic foot ulcers. Pharmacoeconomics, 2003, 21, 1171-83.
5. Persson U, Willis M, Odegaard K, Apelqvist J. The cost-effectiveness of treating diabetic lower extremity ulcers with Becaplermin (Regranex): a core model with an application using Swedish cost data. Value Hlth, 2000, 3, S39-46.
6. Ghamekar O, Persson U, Willis M, Odegaard K. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics, 2001, 19, 767-78.
7. Allenet B, Paree F, Lebrun T, et al. Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the French context. Diabetes Metab, 2000, 26, 125-32.
8. Souchet T, Durand Zaleski I, Hannedouche T, Rodier M, Gaugris S, Passa P. An economic evaluation of Losortan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. Diabetes Metab, 2003, 29, 29-35.
9. UKPDS. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care, 1999, 22, 1125-36.
10. Anonymous. The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention. J Am Med Assoc, 1998, 280, 757-63.
11. Niessen LW, Dijkstra R, Hutubessy R, Rutten GE, Casparie AF. Lifetime health effects and costs of diabetes treatment. Neth J Med, 2003, 61, 355-64.
12. Dolan P. Modeling valuations for EuroQol health states. Med Care, 1997, 35, 1095-108.
13. Busschbach JJ, McDonnell J, Essink-Bot ML, van Hout BA. Estimating parametric relationships between health description and health valuation with an application to the EuroQol EQ-5D. J Health Econ, 1999, 18, 551-71.
14. Feeny DH, Torrance GW, Furlong WJ. Health Utilities Index. Quality of Life and Pharmacoeconomics in Clinical Trials. Lippincost-Raven Publishers; 1996, 239-52.
15. Wagner FW. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle, 1981, 2, 64-122.
16. Apelqvist J, Ragnarson-Tennvall G, Persson U, Larsson J. Diabetic foot ulcers in a multidisciplinary setting: an economic analysis of primary healing and healing with amputation. J Intern Med, 1994, 235, 463-71.
17. Ragnarson-Tennvall G, Apelqvist J. Cost-effective management of diabetic foot ulcers, a review. PharmacoEconomics, 1997, 12, 42-53.
18. nd ed Oxford (UK): Oxford University Press; 1997.
19. Gold M, Patrick D, Torrance G, el al. Identifying and valuing outcomes. Cost-Effectiveness in Health and Medicine. Second ed. Gold M, Siegel J, Russell L, Weinstein M, eds. New York: Oxford University Press; 1996.
20. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal London: National Institute for Clinical Excellence; 2004.
21. CVZ/Dutch Health Insurance Council (Ziekenfondsraad). (CVZ/Dutch Health Insurance Council (Ziekenfondsraad)). Dutch guidelines for pharmacoeconomic research. 1999.
22. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. Second ed Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997.
23. Bleichrodt H, Johannesson M. An experimental test of a theoretical foundation for rating-scale valuations. Med Decis Making, 1997, 17, 208-16.
24. Stolk EA, Busschbach JJ, Caffa M, Meuleman EJ, Rutten FF. Cost utility analysis of sildenafil compared with papaverine-phentolamine injections. Br Med J, 2000, 320, 1165-8.
25. Fryback DG, Lawrence WF, Jr. Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments. Med Decis Making, 1997, 17, 276-84.
26. Stolk EA, Busschbach JJ. Validity and feasibility of the use of condition-specific outcome measures in economic evaluation. Qual Life Res, 2003, 12, 136-71.
27. Ragnarson Tennvall G, Apelqvist J. Health-related quality of life in patients with diabetes mellitus and foot ulcers. J Diab Compl, 2000, 14, 235-41.
28. Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care, 2002, 25, 2238-43.
29. Brown GC, Brown MM, Sharma S, Brown H, Gozum M, Denton P. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications, 2000, 14, 18-24.
30. Sullivan SD, Lew DP, Devine EB, Hakim Z, Reiber GE, Veenstra DL. Health state preference assessment in diabetic peripheral neuropathy. Pharmacoeconomics, 2002, 20, 1079-89.
31. Bleichrodt H. A new explanation for the difference between time trade-off utilities and standard gamble utilities. Health Econ, 2002, 11, 447-56.
32. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GEHM, Wolffenbuttel BHR, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diab Care, 2002, 25, 458-63.
33. Fryback DG. Whose quality of life? or Whose decision? Qual Life Res, 2003, 12, 609-10.
34. Bradley C. Importance of differentiating health status from quality of life (letter). Lancet, 2001, 357, 7-8.